(ABT) Abbott Laboratories - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0028241000
Stock: Pharmaceuticals, Diagnostics, Nutrition, Devices
Total Rating 33
Risk 85
Buy Signal -1.08
| Risk 5d forecast | |
|---|---|
| Volatility | 20.9% |
| Relative Tail Risk | -8.21% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.77 |
| Alpha | -21.05 |
| Character TTM | |
|---|---|
| Beta | -0.071 |
| Beta Downside | 0.070 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.95% |
| CAGR/Max DD | 0.27 |
EPS (Earnings per Share)
Revenue
Description: ABT Abbott Laboratories February 26, 2026
Abbott Laboratories (NYSE: ABT) is a diversified health-care company operating across four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Its portfolio spans generic drugs for gastrointestinal and metabolic disorders, a broad suite of laboratory and point-of-care diagnostics, infant and adult nutrition, and cardiovascular, diabetes, and neuromodulation devices.
In fiscal 2025 Abbott reported record revenue of $45.3 billion, up 7 % year-over-year, with an adjusted earnings per share of $3.45 and an operating margin of 21 %. The Diagnostics segment led growth, expanding 12 % on the back of strong demand for molecular PCR tests and rapid-turnaround COVID-19 and flu assays.
Key sector drivers include an aging global population that fuels chronic-disease treatment and nutrition needs, rising healthcare spending in emerging markets, and accelerating adoption of decentralized, point-of-care testing platforms that shorten diagnostic timelines and improve patient outcomes.
For a deeper, data-rich perspective, you may want to explore Abbott’s metrics on ValueRay.
Headlines to watch out for
- Medical device innovation fuels revenue growth
- Diagnostic product sales drive market share
- Nutritional product demand impacts profitability
- Generic pharmaceutical competition pressures margins
- Regulatory approvals influence product launch timelines
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 6.52b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.73 > 1.0 |
| NWC/Revenue: 21.43% < 20% (prev 22.64%; Δ -1.21% < -1%) |
| CFO/TA 0.11 > 3% & CFO 9.57b > Net Income 6.52b |
| Net Debt (6.54b) to EBITDA (11.63b): 0.56 < 3 |
| Current Ratio: 1.58 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.75b) vs 12m ago 0.06% < -2% |
| Gross Margin: 55.51% > 18% (prev 0.51%; Δ 5.50k% > 0.5%) |
| Asset Turnover: 52.73% > 50% (prev 51.53%; Δ 1.20% > 0%) |
| Interest Coverage Ratio: 26.05 > 6 (EBITDA TTM 11.63b / Interest Expense TTM 341.0m) |
Altman Z'' 5.44
| A: 0.11 (Total Current Assets 26.00b - Total Current Liabilities 16.50b) / Total Assets 86.71b |
| B: 0.57 (Retained Earnings 49.78b / Total Assets 86.71b) |
| C: 0.11 (EBIT TTM 8.88b / Avg Total Assets 84.06b) |
| D: 2.04 (Book Value of Equity 69.31b / Total Liabilities 33.94b) |
| Altman-Z'' Score: 5.44 = AAA |
Beneish M -3.04
| DSRI: 1.08 (Receivables 7.93b/6.92b, Revenue 44.33b/41.95b) |
| GMI: 0.92 (GM 55.51% / 50.90%) |
| AQI: 0.97 (AQ_t 0.55 / AQ_t-1 0.57) |
| SGI: 1.06 (Revenue 44.33b / 41.95b) |
| TATA: -0.04 (NI 6.52b - CFO 9.57b) / TA 86.71b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of ABT shares?
As of March 14, 2026, the stock is trading at USD 110.25 with a total of 7,775,298 shares traded.
Over the past week, the price has changed by -1.40%, over one month by -4.13%, over three months by -15.48% and over the past year by -15.27%.
Over the past week, the price has changed by -1.40%, over one month by -4.13%, over three months by -15.48% and over the past year by -15.27%.
Is ABT a buy, sell or hold?
Abbott Laboratories has received a consensus analysts rating of 4.11.
Therefore, it is recommended to buy ABT.
- StrongBuy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 133.4 | 21% |
| Analysts Target Price | 133.4 | 21% |
ABT Fundamental Data Overview March 11, 2026
P/E Trailing = 30.2011
P/E Forward = 19.305
P/S = 4.4159
P/B = 3.652
P/EG = 4.1675
Revenue TTM = 44.33b USD
EBIT TTM = 8.88b USD
EBITDA TTM = 11.63b USD
Long Term Debt = 9.90b USD (from longTermDebt, last quarter)
Short Term Debt = 3.31b USD (from shortTermDebt, last quarter)
Debt = 15.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.54b USD (from netDebt column, last quarter)
Enterprise Value = 201.88b USD (195.75b + Debt 15.07b - CCE 8.94b)
Interest Coverage Ratio = 26.05 (Ebit TTM 8.88b / Interest Expense TTM 341.0m)
EV/FCF = 27.30x (Enterprise Value 201.88b / FCF TTM 7.39b)
FCF Yield = 3.66% (FCF TTM 7.39b / Enterprise Value 201.88b)
FCF Margin = 16.68% (FCF TTM 7.39b / Revenue TTM 44.33b)
Net Margin = 14.72% (Net Income TTM 6.52b / Revenue TTM 44.33b)
Gross Margin = 55.51% ((Revenue TTM 44.33b - Cost of Revenue TTM 19.72b) / Revenue TTM)
Gross Margin QoQ = 57.05% (prev 55.75%)
Tobins Q-Ratio = 2.33 (Enterprise Value 201.88b / Total Assets 86.71b)
Interest Expense / Debt = 0.28% (Interest Expense 42.0m / Debt 15.07b)
Taxrate = 24.68% (582.0m / 2.36b)
NOPAT = 6.69b (EBIT 8.88b * (1 - 24.68%))
Current Ratio = 1.58 (Total Current Assets 26.00b / Total Current Liabilities 16.50b)
Debt / Equity = 0.29 (Debt 15.07b / totalStockholderEquity, last quarter 52.13b)
Debt / EBITDA = 0.56 (Net Debt 6.54b / EBITDA 11.63b)
Debt / FCF = 0.89 (Net Debt 6.54b / FCF TTM 7.39b)
Total Stockholder Equity = 50.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.76% (Net Income 6.52b / Total Assets 86.71b)
RoE = 12.89% (Net Income TTM 6.52b / Total Stockholder Equity 50.62b)
RoCE = 14.68% (EBIT 8.88b / Capital Employed (Equity 50.62b + L.T.Debt 9.90b))
RoIC = 10.50% (NOPAT 6.69b / Invested Capital 63.75b)
WACC = 5.26% (E(195.75b)/V(210.82b) * Re(5.65%) + D(15.07b)/V(210.82b) * Rd(0.28%) * (1-Tc(0.25)))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.03%
[DCF] Terminal Value 86.76% ; FCFF base≈6.98b ; Y1≈7.29b ; Y5≈8.43b
[DCF] Fair Price = 140.3 (EV 250.31b - Net Debt 6.54b = Equity 243.76b / Shares 1.74b; r=5.90% [WACC]; 5y FCF grow 4.83% → 2.90% )
EPS Correlation: -10.61 | EPS CAGR: -3.73% | SUE: 0.52 | # QB: 0
Revenue Correlation: 20.64 | Revenue CAGR: -0.99% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.39 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+6 | Analysts=24
EPS current Year (2026-12-31): EPS=5.68 | Chg7d=+0.000 | Chg30d=-0.000 | Revisions Net=+3 | Growth EPS=+10.2% | Growth Revenue=+8.1%
EPS next Year (2027-12-31): EPS=6.24 | Chg7d=+0.000 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+10.0% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +0.38 (11 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.6% (Discount Rate 7.9% - Earnings Yield 3.3%)
[Growth] Growth Spread = +2.1% (Analyst 6.8% - Implied 4.6%)
P/E Forward = 19.305
P/S = 4.4159
P/B = 3.652
P/EG = 4.1675
Revenue TTM = 44.33b USD
EBIT TTM = 8.88b USD
EBITDA TTM = 11.63b USD
Long Term Debt = 9.90b USD (from longTermDebt, last quarter)
Short Term Debt = 3.31b USD (from shortTermDebt, last quarter)
Debt = 15.07b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.54b USD (from netDebt column, last quarter)
Enterprise Value = 201.88b USD (195.75b + Debt 15.07b - CCE 8.94b)
Interest Coverage Ratio = 26.05 (Ebit TTM 8.88b / Interest Expense TTM 341.0m)
EV/FCF = 27.30x (Enterprise Value 201.88b / FCF TTM 7.39b)
FCF Yield = 3.66% (FCF TTM 7.39b / Enterprise Value 201.88b)
FCF Margin = 16.68% (FCF TTM 7.39b / Revenue TTM 44.33b)
Net Margin = 14.72% (Net Income TTM 6.52b / Revenue TTM 44.33b)
Gross Margin = 55.51% ((Revenue TTM 44.33b - Cost of Revenue TTM 19.72b) / Revenue TTM)
Gross Margin QoQ = 57.05% (prev 55.75%)
Tobins Q-Ratio = 2.33 (Enterprise Value 201.88b / Total Assets 86.71b)
Interest Expense / Debt = 0.28% (Interest Expense 42.0m / Debt 15.07b)
Taxrate = 24.68% (582.0m / 2.36b)
NOPAT = 6.69b (EBIT 8.88b * (1 - 24.68%))
Current Ratio = 1.58 (Total Current Assets 26.00b / Total Current Liabilities 16.50b)
Debt / Equity = 0.29 (Debt 15.07b / totalStockholderEquity, last quarter 52.13b)
Debt / EBITDA = 0.56 (Net Debt 6.54b / EBITDA 11.63b)
Debt / FCF = 0.89 (Net Debt 6.54b / FCF TTM 7.39b)
Total Stockholder Equity = 50.62b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.76% (Net Income 6.52b / Total Assets 86.71b)
RoE = 12.89% (Net Income TTM 6.52b / Total Stockholder Equity 50.62b)
RoCE = 14.68% (EBIT 8.88b / Capital Employed (Equity 50.62b + L.T.Debt 9.90b))
RoIC = 10.50% (NOPAT 6.69b / Invested Capital 63.75b)
WACC = 5.26% (E(195.75b)/V(210.82b) * Re(5.65%) + D(15.07b)/V(210.82b) * Rd(0.28%) * (1-Tc(0.25)))
Discount Rate = 5.65% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -0.03%
[DCF] Terminal Value 86.76% ; FCFF base≈6.98b ; Y1≈7.29b ; Y5≈8.43b
[DCF] Fair Price = 140.3 (EV 250.31b - Net Debt 6.54b = Equity 243.76b / Shares 1.74b; r=5.90% [WACC]; 5y FCF grow 4.83% → 2.90% )
EPS Correlation: -10.61 | EPS CAGR: -3.73% | SUE: 0.52 | # QB: 0
Revenue Correlation: 20.64 | Revenue CAGR: -0.99% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.39 | Chg7d=+0.000 | Chg30d=-0.001 | Revisions Net=+6 | Analysts=24
EPS current Year (2026-12-31): EPS=5.68 | Chg7d=+0.000 | Chg30d=-0.000 | Revisions Net=+3 | Growth EPS=+10.2% | Growth Revenue=+8.1%
EPS next Year (2027-12-31): EPS=6.24 | Chg7d=+0.000 | Chg30d=+0.006 | Revisions Net=+2 | Growth EPS=+10.0% | Growth Revenue=+7.5%
[Analyst] Revisions Ratio: +0.38 (11 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.6% (Discount Rate 7.9% - Earnings Yield 3.3%)
[Growth] Growth Spread = +2.1% (Analyst 6.8% - Implied 4.6%)